Raymond James Downgrades Phase Forward (PFWD) to Outperform
More News related to PFWD
- Phase Forward to Present at the 11th Annual Needham Growth Stock Conference
- U.S. Department of Defense Chooses Phase Forward to Support FDA-Sponsored Drug Safety Initiative
- Phase Forward to Participate in the Nasdaq OMX Healthcare Industry Forum
- NASDAQ OMX and Leerink Swann to Co-Host HealthCare Industry Forum
- World Economic Forum Selects Phase Forward as Technology Pioneer 2009
More News related to Downgrades
- ARGUS Downgrades Smith International (SII) to Hold
- Cantor Fitzgerald Downgrades Audiocodes (AUDC) to Hold After Negative 4Q Preannouncement
- MDB Capital Downgrades Ener1 (HEV) to Sell, Suspends Earnings Model and Valuation on Stock No Longer Justified
- DA Davidson Downgrades Ambassadors Group (EPAX) to Neutral
- SunTrust Downgrades Ruby Tuesday, Inc. (RT) to Neutral
Raymond James downgrades Phase Forward (Nasdaq: PFWD) from Strong Buy to Outperform.
Phase Forward Incorporated provides integrated enterprise-level software products, services, and hosted solutions for use in clinical trial and drug safety monitoring activities in the United States, the United Kingdom, France, and the Asia Pacific.
Related Categories
DowngradesStocks Mentioned
+0.39Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
